IMPACT BIOMEDICAL INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
SEC declared effective on October 23, 2026 the Form F-4 registration statement for Impact Biomedical's proposed business combination with Zoar Limited. Impact stockholders will vote on November 13, 2026 to approve the merger. Upon closing, the combined company will operate as Zoar Limited and trade on NYSE American under ticker ZOAR, focusing on active pharmaceutical ingredients and orphan drug development.
Why this rating
Business combination is transformational for $7.6M market-cap company; represents fundamental change in business model and ownership. Regulatory milestone achieved; stockholder vote imminent; material dilution/restructuring likely but specifics unclear from filing.
Tradability signal
NO TRADE
No trade: positive news with only -0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.13% over 4 hrs, n=351). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $4.01 | +10 min · unknown $4.01 ▲ 0.00% | +30 min · unknown $4.16 ▲ 3.74% | +1 hr · unknown $4.16 ▲ 3.74% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.